X

Drug Profile

AT 220

Alternative Names: AT-220

Latest Information Update: 22 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Unknown
Developer Arecor
Class
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Unspecified

Most Recent Events

17 Nov 2023 Launched for Unspecified in Europe (Parenteral)
20 Jul 2023 Arecor Therapeutics anticipates US FDA approval for AT 220 in US in second half of 2023
05 Jul 2023 Arecor Therapeutics enters into a collaboration agreement with an undisclosed global pharmaceutical and healthcare company to support the ongoing development of AT 220 biosimilar product

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com